Hypertension Management and End Organ Protection: Focus on Aliskiren
作者： Toshio Imanishi , Hiroto Tsujioka , Takashi Akasaka
DOI: 10.4137/CMT.S1980
关键词:
摘要: The renin-angiotensin system (RAS) activity is a key factor in the pathophysiology and development of hypertension, atherosclerosis, heart failure, renal disease. It unclear whether angiotensin-converting-enzyme (ACE) inhibitors angiotensin-receptor blockers (ARBs) have fully delivered expected reductions cardiovascular risk. In fact, optimized RAS suppression difficult to achieve with these agents, partly because ACE ARBs both activate compensatory feedback mechanisms that result renin release increase plasma (PRA). Molecular modeling was used develop aliskiren, potent, low-molecular-weight, nonpeptide, direct inhibitor sufficient bioavailability produce sustained PRA after oral administration. This report discusses action their pharmacokinetic properties. addition, also evaluates available data regarding effects aliski...
sagepub.com
sci-hub.se 参考文章(42)
W Fischli, J P Clozel, Discovery of remikiren as the first orally active renin inhibitor Drug Research. ,vol. 43, pp. 260- 262 ,(1993)
A. Fukamizu, K. Sugimura, E. Takimoto, F. Sugiyama, M.S. Seo, S. Takahashi, T. Hatae, N. Kajiwara, K. Yagami, K. Murakami, Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes Journal of Biological Chemistry. ,vol. 268, pp. 11617- 11621 ,(1993) , 10.1016/S0021-9258(19)50246-0
Michael R. Goldberg, Thomas E. Bradstreet, Edward J. McWilliams, Wesley K. Tanaka, Stephanie Lipert, Thorir D. Bjornsson, Scott A. Waldman, Barbara Osborne, Lisa Pivadori, George Lewis, Robert Blum, Theodore Herman, Paul A. Abraham, Charles N. Halstenson, Man-Wai Lo, Hannah Lu, Reynold Spector, Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients Hypertension. ,vol. 25, pp. 37- 46 ,(1995) , 10.1161/01.HYP.25.1.37
Michel Azizi, Randy Webb, Juerg Nussberger, Norman K Hollenberg, Renin inhibition with aliskiren: where are we now, and where are we going? Journal of Hypertension. ,vol. 24, pp. 243- 256 ,(2006) , 10.1097/01.HJH.0000202812.72341.99
A Delabays, J Nussberger, M Porchet, B Waeber, P Hoyos, R Boger, H Glassman, H D Kleinert, R Luther, H R Brunner, Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension. ,vol. 13, pp. 941- 947 ,(1989) , 10.1161/01.HYP.13.6.941
R S Boger, H N Glassman, J H Cavanaugh, P J Schmitz, J Lamm, D Moyse, A Cohen, H D Kleinert, R R Luther, Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension. ,vol. 15, pp. 835- 840 ,(1990) , 10.1161/01.HYP.15.6.835
Toshio KUSHIRO, Hiroshige ITAKURA, Yoshihisa ABO, Hiromi GOTOU, Shinji TERAO, Deborah L. KEEFE, Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension Hypertension Research. ,vol. 29, pp. 997- 1005 ,(2006) , 10.1291/HYPRES.29.997
Sujata Vaidyanathan, Christine Reynolds, Ching-Ming Yeh, Marie-Noëlle Bizot, Hans Armin Dieterich, Dan Howard, William P. Dole, Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects The Journal of Clinical Pharmacology. ,vol. 47, pp. 453- 460 ,(2007) , 10.1177/0091270006297921
D. J. Kelly, Y. Zhang, G. Moe, G. Naik, R. E. Gilbert, Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats Diabetologia. ,vol. 50, pp. 2398- 2404 ,(2007) , 10.1007/S00125-007-0795-9
M. Szelke, B. Leckie, A. Hallett, D. M. Jones, J. Sueiras, B. Atrash, A. F. Lever, Potent new inhibitors of human renin Nature. ,vol. 299, pp. 555- 557 ,(1982) , 10.1038/299555A0